newsfilter
← Latest News
GlobeNewswire·

Chemed Reports Second-Quarter 2026 Results

CHE
  • Chemed Corporation reported consolidated revenue of $673.3 million for the quarter ended June 30, 2026, an 8.8% increase from the prior year.
  • GAAP diluted earnings per share rose 43.7% to $5.13, while adjusted diluted earnings per share increased 41.9% to $6.06.
  • VITAS segment net patient revenue grew 11.9% to $443.3 million, driven by a 6.1% increase in average daily census.
  • VITAS recorded only $500,000 in Medicare Cap billing limitations for the quarter, a significant decrease from $16.4 million in the prior year.
  • VITAS adjusted EBITDA, excluding Medicare Cap, increased 20.6% to $80.6 million, with an adjusted EBITDA margin of 18.2%.
  • Roto-Rooter segment revenue increased 3.3% to $229.9 million, with commercial revenue up 6.8% and residential revenue up 1.7%.
  • Roto-Rooter adjusted EBITDA remained essentially flat at $48.5 million, while the adjusted EBITDA margin declined 77 basis points to 21.1%.
  • Chemed held $40.2 million in cash equivalents and $140.0 million in long-term debt as of June 30, 2026.
  • The company repurchased 210,000 shares during the quarter for $89.8 million, reducing outstanding shares by approximately 10.5% over the trailing 12 months.
  • Chemed updated full-year 2026 adjusted EPS guidance to a range of $25.00 to $25.75, up from the previous range of $24.00 to $24.75.
  • Revised guidance anticipates VITAS ADC growth between 5.75% and 6.25%, with revenue growth excluding Medicare Cap projected at 8.25% to 9.25%.
  • Roto-Rooter full-year revenue growth guidance remains unchanged at 3.0% to 3.5%, with an estimated adjusted EBITDA margin of 21.5% to 22.5%.
  • Chemed will host a conference call on July 29, 2026, to discuss the quarterly results and business updates.